



# SEQUENCE LISTING

<110> ~~SECRET~~, Els A.J.M.  
Hunt, Donald F.  
Engelhard, Victor H.

<120> HA-1 epitopes and uses thereof

<130> 2183-6047US

<140> 10/623,176

<141> 2003-07-18

<150> 09/489,760

<151> 2000-01-21

<150> EP 97202303.0

<151> 1997-07-23

<150> PCT/NL98/00424

<151> 1998-07-23

<150> JP 2000-504165

<151> 2000-01-24

<160> 101

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>

<221> SITE

<222> (1)..(9)

<400> 1

Val Leu Xaa Asp Asp Leu Leu Glu Ala

1

5

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 2

Val Leu His Asp Asp Leu Leu Glu Ala  
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>

<221> SITE

<222> (1)..(9)

<400> 3

Lys Glu Cys Val Leu Xaa Asp Asp Leu  
1 5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 4

Lys Glu Cys Val Leu His Asp Asp Leu  
1 5

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 5

Lys Glu Cys Val Leu Arg Asp Asp Leu

1

5

<210> 6

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 6

Lys Glu Cys Val Leu His Asp Asp Leu Leu

1

5

10

<210> 7

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 7

Lys Glu Cys Val Leu Arg Asp Asp Leu Leu

1

5

10

<210> 8

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be R or H

<220>

<221> SITE

<222> (1)..(10)

<400> 8

Lys Glu Cys Val Leu Xaa Asp Asp Leu Leu

1

5

10

<210> 9

<211> 10

<212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: peptide  
         capable of binding HLA-A2.1  
  
 <220>  
 <221> SITE  
 <222> (1)..(10)  
  
 <400> 9  
 Phe Leu Pro Ser Asp Cys Phe Pro Ser Val  
     1                    5                    10  
  
  
 <210> 10  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 10  
 Val Leu Arg Asp Asp Leu Leu Glu Ala  
     1                    5  
  
  
 <210> 11  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HLA-A3 binder  
         positive control peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 11  
 Lys Gln Ser Ser Lys Ala Leu Gln Arg  
     1                    5  
  
  
 <210> 12  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>

<223> Description of Artificial Sequence: HLA-B60 binder  
positive control peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 12

Lys Glu Ser Thr Leu His Leu Val Leu  
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence  
revealed from peptide candidate m/z 550 wherein X  
can be I or L

<220>

<221> SITE

<222> (1)..(9)

<400> 13

Tyr Xaa Thr Asp Arg Val Met Thr Val  
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence of  
peptide candidate m/z 513 wherein X can be L or I

<220>

<221> SITE

<222> (1)..(9)

<400> 14

Val Xaa His Asp Asp Xaa Xaa Glu Ala  
1 5

<210> 15

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(8)

<400> 15  
Val Leu His Asp Leu Leu Glu Ala  
1 5

<210> 16  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: reverse primer

<220>  
<221> misc\_feature  
<222> (1)..(25)

<400> 16  
gctcctgcat gacgctctgt ctgca 25

<210> 17  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 (I)  
forward primer

<220>  
<221> misc\_feature  
<222> (1)..(24)

<400> 17  
gacgtcgtcg aggacatctc ccat 24

<210> 18  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: reverse primer

<220>  
<221> misc\_feature  
<222> (1)..(25)

<400> 18  
gaaggccaca gcaatcgtct ccagg 25

<210> 19  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer H1  
<220>

<221> misc\_feature  
<222> (1)..(30)

<400> 19  
ccttgagaaa cttaaggagt gtgtgctgca 30

<210> 20  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer R1

<220>  
<221> misc\_feature  
<222> (1)..(30)

<400> 20  
ccttgagaaa cttaaggagt gtgtgttgcg 30

<210> 21  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: forward primer

<220>  
<221> misc\_feature  
<222> (1)..(33)

<400> 21  
ccggcatgga cgtcgtcgag gacatctccc atc 33

<210> 22  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse primer

<220>

<221> misc\_feature

<222> (1)..(30)

<400> 22

ctacttcagg ccacagcaat cgtctccagg

30

<210> 23

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 23

Glu Cys Val Leu Arg Asp Asp Leu Leu

1

5

<210> 24

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide  
wherein X can be H or R

<220>

<221> SITE

<222> (1)..(10)

<400> 24

Val Leu Xaa Asp Asp Leu Leu Glu Ala Arg

1

5

10

<210> 25

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CFL5c8 primer  
wherein n is unknown

<220>

<221> misc\_feature



<222> (1)..(32)

<400> 25

ccccccccc ccccgctcta gannnnnnnn nn

32

<210> 26

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CFL5cT primer  
wherein n is unknown

<220>

<221> misc\_feature

<222> (1)..(39)

<400> 26

ccccccccc ccccgctcta gatttttttt tttttttvn

39

<210> 27

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CP2 primer

<220>

<221> misc\_feature

<222> (1)..(27)

<400> 27

tcagaattca tgcccccccc ccccccc

27

<210> 28

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 (I)  
reverse primer

<220>

<221> misc\_feature

<222> (1)..(24)

<400> 28

gaaggccaca gcaatcgtct ccag

24

<210> 29

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 (II)  
forward primer

<220>

<221> misc\_feature

<222> (1)..(21)

<400> 29

acactgctgt cgtgtgaagt c

21

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 (II)  
reverse primer

<220>

<221> misc\_feature

<222> (1)..(20)

<400> 30

tcaggccctg ctgtactgca

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CD45 forward  
primer

<220>

<221> misc\_feature

<222> (1)..(20)

<400> 31

ctgaaggaga ccattggtga

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CD45 reverse

primer

<220>

<221> misc\_feature

<222> (1)..(20)

<400> 32

ggtactggta cacagttcga

20

<210> 33

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1  
polymorphic region wherein X can be H or R

<220>

<221> SITE

<222> (1)..(17)

<400> 33

Glu Lys Leu Lys Glu Cys Val Leu Xaa Asp Asp Leu Leu Glu Ala Arg  
1 5 10 15

Arg

<210> 34

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 34

Glu Lys Leu Lys Glu Cys Val Leu His  
1 5

<210> 35

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 35  
 Glu Lys Leu Lys Glu Cys Val Leu Arg  
   1                  5  
  
 <210> 36  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 36  
 Lys Leu Lys Glu Cys Val Leu His Asp  
   1                  5  
  
 <210> 37  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 37  
 Lys Leu Lys Glu Cys Val Leu Arg Asp  
   1                  5  
  
 <210> 38  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(9)  
  
 <400> 38  
 Leu Lys Glu Cys Val Leu His Asp Asp

1

5

<210> 39

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 39

Leu Lys Glu Cys Val Leu Arg Asp Asp

1

5

<210> 40

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 40

Glu Cys Val Leu His Asp Asp Leu Leu

1

5

<210> 41

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 41

Cys Val Leu His Asp Asp Leu Leu Glu

1

5

<210> 42

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(9)

<400> 42

Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5

<210> 43

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 43

Val Leu His Asp Asp Leu Leu Glu Ala Arg  
1 5 10

<210> 44

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(10)

<400> 44

Val Leu Arg Asp Asp Leu Leu Glu Ala Arg  
1 5 10

<210> 45

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

```

<221> SITE
<222> (1)..(9)

<400> 45
Leu His Asp Asp Leu Leu Glu Ala Arg
 1           5

<210> 46
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HA-1 peptide

<220>
<221> SITE
<222> (1)..(9)

<400> 46
Leu Arg Asp Asp Leu Leu Glu Ala Arg
 1           5

<210> 47
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HA-1 peptide

<220>
<221> SITE
<222> (1)..(9)

<400> 47
His Asp Asp Leu Leu Glu Ala Arg Arg
 1           5

<210> 48
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: HA-1 peptide

<220>
<221> SITE
<222> (1)..(9)

<400> 48
Arg Asp Asp Leu Leu Glu Ala Arg Arg
 1           5

```

<210> 49  
 <211> 29  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: 29 amino acid  
       long HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(29)  
  
 <400> 49  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
   1                  5                  10                  15  
  
 Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
           20                  25  
  
  
 <210> 50  
 <211> 14  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(14)  
  
 <400> 50  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu  
   1                  5                  10  
  
  
 <210> 51  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: HA-1 peptide  
  
 <220>  
 <221> SITE  
 <222> (1)..(27)  
  
 <400> 51  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
   1                  5                  10                  15



Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 52  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(19)

<400> 52  
His Asp Asp Leu Leu Glu Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
1 5 10 15

Gly Glu Ala

<210> 53  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(22)

<400> 53  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 54  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(13)

<400> 54

Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu  
1 5 10

<210> 55

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(25)

<400> 55

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 56

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(12)

<400> 56

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp  
1 5 10

<210> 57

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE

<222> (1)..(17)

<400> 57

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
 1 5 10 15

Ala

<210> 58  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(10)

<400> 58  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu  
 1 5 10

<210> 59  
 <211> 29  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: 29 amino acid  
 long HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(29)

<400> 59  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
 20 25

<210> 60  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(27)

<400> 60  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 61  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(28)

<400> 61  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu  
20 25

<210> 62  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(14)

<400> 62  
Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu  
1 5 10

<210> 63  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: HA-1 peptide

<220>  
<221> SITE  
<222> (1)..(22)

<400> 63  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
           1                          5                          10                          15

Ala Arg Arg Pro Arg Ala  
                           20

<210> 64  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(13)

<400> 64  
 Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu  
           1                          5                          10

<210> 65  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(12)

<400> 65  
 Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
           1                          5                          10

<210> 66  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(26)

<400> 66  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu

|   |    |    |    |
|---|----|----|----|
| 1                                       | 5  | 10 | 15 |
| Ala Arg Arg Pro Arg Ala His Glu Cys Leu |    |    |    |
|   | 20 | 25 |    |

<210> 67  
 <211> 25  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(25)

|   |
|---|
| <400> 67  |
| Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu |
| 1 5 10 15   |

|                                     |
|-------------------------------------|
| Ala Arg Arg Pro Arg Ala His Glu Cys |
| 20 25                               |

<210> 68  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(12)

|   |
|---|
| <400> 68  |
| Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp |
| 1 5 10  |

<210> 69  
 <211> 17  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(17)

<400> 69

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala

<210> 70  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(19)

<400> 70  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg

<210> 71  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(21)

<400> 71  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg Pro Arg  
 20

<210> 72  
 <211> 23  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>

<221> SITE  
 <222> (1)..(23)  
  
 <400> 72  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
     1                    5                    10                    15  
  
 Ala Arg Arg Pro Arg Ala His  
             20  
  
 <210> 73  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: KIAA0223  
       sequence derived from a presumed HA-1 negative  
       individual  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(38)  
  
 <400> 73  
 gagtgtgtgt tgcgtgacga cctccttgag gcccgccg 38  
  
 <210> 74  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: KIAA0223  
       sequence derived from a presumed HA-1 negative  
       individual  
  
 <220>  
 <221> SITE  
 <222> (1)..(13)  
  
 <400> 74  
 Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
     1                    5                    10  
  
 <210> 75  
 <211> 38  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: KIAA0223  
       sequence derived from a presumed HA-1 homozygous  
       positive individual



<220>  
 <221> misc\_feature  
 <222> (1)..(38)  
  
 <400> 75  
 gagtgtgtgc tgcattgacga cctccttgag gcccgcgcg

38

<210> 76  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: KIAA0223  
 sequence derived from a presumed HA-1 homozygous  
 positive individual

<220>  
 <221> SITE  
 <222> (1)..(13)

<400> 76  
 Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
 1 5 10

<210> 77  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: HA-1 peptide

<220>  
 <221> SITE  
 <222> (1)..(9)

<400> 77  
 Tyr Ile Gly Glu Val Leu Val Ser Val  
 1 5

<210> 78  
 <211> 29  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: a 29 amino acid long HA-1A peptide

<400> 78  
  
 Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 79  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 79

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu  
1 5 10

<210> 80  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 80

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 81  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 81

His Asp Asp Leu Leu Glu Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
1 5 10 15

Gly Glu Ala

<210> 82  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 82

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 83  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 83

Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu  
1 5 10

<210> 84  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 84

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 85  
<211> 12  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 85

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp  
1 5 10

<210> 86

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 86

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu His Asp Asp Leu Leu Glu  
1 5 10 15

Ala

<210> 87

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1A peptide

<400> 87

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu  
1 5 10

<210> 88

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: a 29 amino acid long HA-1R peptide

<400> 88

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu Ala  
20 25

<210> 89  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 89

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly  
20 25

<210> 90  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 90

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu Gly Glu  
20 25

<210> 91  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 91

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu  
1 5 10

<210> 92  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 92

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala  
20

<210> 93  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 93

Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu  
1 5 10

<210> 94  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 94

Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10

<210> 95  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 95

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys Leu  
20 25

<210> 96

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 96

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His Glu Cys  
20 25

<210> 97

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 97

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp  
1 5 10

<210> 98

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 98

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala

<210> 99  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 99

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg

<210> 100  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 100

Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
 1 5 10 15

Ala Arg Arg Pro Arg  
 20

<210> 101  
 <211> 23  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: in vitro proteasomal cleavage of a 29 amino acid long HA-1R peptide

<400> 101



Gly Leu Glu Lys Leu Lys Glu Cys Val Leu Arg Asp Asp Leu Leu Glu  
1 5 10 15

Ala Arg Arg Pro Arg Ala His  
20